MSIS-29 and SF-36 Scores as Outcomes in Secondary Progressive MS Trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials
Mult. Scler. 2022 Sep 01;28(10)1606-1619, EM Strijbis, P Repovic, J Mostert, JD Bowen, BM Uitdehaag, G Cutter, MW KochFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.